ciforadenant   Click here for help

GtoPdb Ligand ID: 10190

Synonyms: CPI-444 | CPI444 | V-81444 | V81444
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Ciforadenant (CPI-444) is an orally active adenosine A2A receptor antagonist.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 127
Molecular weight 407.17
XLogP 0.65
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Nc1nc(c2ccc(o2)C)c2c(n1)n(nn2)Cc1cccc(n1)COC1COCC1
Isomeric SMILES Nc1nc(c2ccc(o2)C)c2c(n1)n(nn2)Cc1cccc(n1)CO[C@@H]1COCC1
InChI InChI=1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)/t15-/m0/s1
InChI Key KURQKNMKCGYWRJ-HNNXBMFYSA-N
No information available.
Summary of Clinical Use Click here for help
Ciforadenant (CPI-444) is being evaluated for immuno-oncology potential in combination with anti-PD-L1 checkpoint inhibitor atezolizumab (Phase 1/1b NCT02655822). Preclinical studies indicate that ciforadenant enhances the antitumour responses to both anti-PD-L1- and anti-CTLA-4-induced checkpoint inhibition in vivo [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02655822 Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Phase 1 Interventional Corvus Pharmaceuticals, Inc.